Home > Oncology > WCLC 2019 > Immuno-Oncology > Nivolumab + Ipilimumab Safe First-line Treatment for NSCLC Patients with Comorbidities

Nivolumab + Ipilimumab Safe First-line Treatment for NSCLC Patients with Comorbidities

Presented By
Dr Fabrice Barlesi, Hôpitaux de Marseille, France
Conference
WCLC 2019
Trial
Phase 4, CHECKMATE-817

Data from the CHECKMATE-817 trial demonstrated that the combination of nivolumab and ipilimumab is a safe first-line treatment option for patients with advanced non-small-cell lung cancer (NSCLC) who also harbour comorbidities or a poor Eastern Cooperative Oncology Group (ECOG) performance status. The combination was shown to have a consistent safety profile in these special populations.

Until recently, data on immunotherapy in patients with advanced NSCLC and poor performance status or other comorbidities were limited. CheckMate 817 –a multi-cohort, open-label phase 3b/4 study– investigated safety and efficacy of flat-dose nivolumab + weight-based low-dose ipilimumab in patients with advanced NSCLC. Dr Fabrice Barlesi (Hôpitaux de Marseille, France) evaluated this regimen as first-line treatment in a reference population (cohort A, n=391, ECOG performance status 0-1) and a special population (cohort A1, n=198) consisting of patients with ECOG performance ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on